Michele Donato🇺🇸🇨🇦MD FACP MBA
banner
mdonatobmt.bsky.social
Michele Donato🇺🇸🇨🇦MD FACP MBA
@mdonatobmt.bsky.social
Stem Cell Transplantation Cellular Therapy
Breaking the cycle: PRMTs and secondary HLH relief url:https://ashpublications.org/bloodadvances/article/9/10/2436/537247/Breaking-the-cycle-PRMTs-and-secondary-HLH-relief
May 17, 2025 at 1:39 PM
Fatal Recurrence of IEC-HS Following Autologous Stem Cell Boost in Patients Receiving BCMA CAR-T Cell Therapy

Blood Adv bloodadvances.2025016346.
doi.org/10.1182/bloo...
Fatal Recurrence of IEC-HS Following Autologous Stem Cell Boost in Patients Receiving BCMA CAR-T Cell Therapy
Snegha Ananth, Nancy Eunice Torres, Bita Sahaf, Lakha Mikkilineni, Sebastian Fernandez-Pol, Darren Salmi, Robert S. Negrin, Parveen Shiraz, Melody Smith, S
doi.org
May 13, 2025 at 10:25 AM
Successful treatment of multi-hit TP53-mutated MDS with erythroid predominance using allo-HSCT and ruxolitinib

Ann Hematol (2025). doi.org/10.1007/s002...
Successful treatment of multi-hit TP53-mutated myelodysplastic syndromes with erythroid predominance using allogeneic stem cell transplantation and ruxolitinib - Annals of Hematology
TP53-mutated myelodysplastic syndrome (MDS) and acute erythroid leukemia (AEL) with complex karyotype have a very poor prognosis. The upregulation of the JAK-STAT pathway has been implicated in their ...
doi.org
May 7, 2025 at 8:52 PM
Reposted by Michele Donato🇺🇸🇨🇦MD FACP MBA
Relapsed Burkitt’s lymphoma is nearly always fatal. Three patients had a complete metabolic response with the combination of the bispecific antibody glofitamab and the antibody–drug conjugate polatuzumab vedotin. Full correspondence: nej.md/4lS7kfe

#MedSky #Hematology
May 4, 2025 at 4:03 PM
Outcomes of acute myeloid leukemia with KMT2A (MLL) rearrangement: a multicenter study of TROPHY group

Blood Cancer J. 15, 84 (2025). doi.org/10.1038/s414...
#astct #aml #ash
May 4, 2025 at 11:23 AM
Real-world effectiveness of IVIG replacement for hypogammaglobulinemia and infections in MM

Blood (2024) 144 (Supplement 1): 707.
doi.org/10.1182/bloo...

Significant reductions in infections and infections requiring antimicrobials
Real-World Effectiveness of Immunoglobulin Replacement Therapy on Hypogammaglobulinemia and Infectious Complications in Patients with Multiple Myeloma
Disclosures. O'Donnell:Pfizer: Honoraria; Takeda: Consultancy; Janssen: Honoraria; BMS: Honoraria; Sanofi: Honoraria; Natera: Other: Steering committee; Ex
doi.org
May 1, 2025 at 10:20 AM
Combination of disease burden before allo-HSCTand early post-transplant MRD predicts survival in AML

Ann Hematol (2025). doi.org/10.1007/s002...
#lls #astct #aml
April 30, 2025 at 9:43 AM
GVHD prophylaxis in matched related HSCT: Why PTCy can be recommended a study by the EBMT transplant complications working party

Leukemia (2025). doi.org/10.1038/s413...
#astct #lls #ash
April 22, 2025 at 10:21 AM
Diagnostic accuracy of liver stiffness measurement for VOD/SOS after HSCT. ELASTOVOD STUDY:

Bone Marrow Transplant (2025). doi.org/10.1038/s414...
<6.5kPa rule out vod; >25 kPa rule in VOD; 9.5 kPa optimal cut off
#astct #ash
Diagnostic accuracy of liver stiffness measurement for the diagnosis of veno-occlusive disease/sinusoidal obstruction syndrome after hematopoietic stem cell transplantation (HSCT), the ELASTOVOD STUDY...
Bone Marrow Transplantation - Diagnostic accuracy of liver stiffness measurement for the diagnosis of veno-occlusive disease/sinusoidal obstruction syndrome after hematopoietic stem cell...
doi.org
April 21, 2025 at 10:39 AM
Reposted by Michele Donato🇺🇸🇨🇦MD FACP MBA
Excellent review article by @bldcancerdoc.bsky.social Outpatient Administration of Chimeric Antigen Receptor T-Cell Therapy Using Remote Patient Monitoring | JCO Oncology Practice ascopubs.org/doi/10.1200/... @acochran12733.bsky.social @oncoalert.bsky.social
April 19, 2025 at 11:42 PM
Teduglutide for treatment-refractory severe GI aGVHD
www.nature.com/articles/s41...
#astct #gvhd
April 17, 2025 at 11:20 AM
Less frequent complications following CAR T-cell: HLH, GVHD, TMA, coag disorders and 2nd malignancies: recommendations from the EBMT Practice Harmonization and Guidelines Committee

Bone Marrow Transplant (2025). doi.org/10.1038/s414...
April 11, 2025 at 7:42 PM
Improved post-transplant outcomes for elderly AML with FLU/BU4 rather than conventional MAC regimens.

Bone Marrow Transplant (2025). doi.org/10.1038/s414...
#LLS #astct #AML
April 10, 2025 at 10:26 AM
Reposted by Michele Donato🇺🇸🇨🇦MD FACP MBA
ASTCT's journal, 'Transplantation and Cellular Therapy,' recently released a new supplement dedicated to the latest research, challenges & innovations in Tumor-Infiltrating Lymphocyte (TIL) therapy, supported through an educational grant provided by Iovance Biotherapeutics: ow.ly/MviL50VlXTi
April 1, 2025 at 5:06 PM
ASCT for R/R Large B Cell Lymphoma: Multicenter GETH-TC/GELTAMO Study

doi.org/10.1182/bloo...
#lls #astct #bmt
April 3, 2025 at 1:01 AM
Allo HSCT Using FLU-BU3 and ATG With Strategic Donor Lymphocyte Infusion in Older Patients With Myeloid Malignancy. www.scilit.com/publications...
March 31, 2025 at 10:08 AM
HSCT & quizartinib in newly diagnosed AML FLT-3 ITD: the QuANTUM-First trial

doi.org/10.3324/haem...
#AML #ASTCT
March 24, 2025 at 6:00 PM
Reposted by Michele Donato🇺🇸🇨🇦MD FACP MBA
Congrats to @cwynkate2.bsky.social, Martin Pule for early results of a CAR-T approach targeting TCR constant regions in peripheral T cell lymphomas. Long awaited results of a creative solution to the vexing problem of targeting T cell antigens in cancer. #immunotherapy www.nature.com/articles/s41...
TRBC1-CAR T cell therapy in peripheral T cell lymphoma: a phase 1/2 trial - Nature Medicine
In the dose-escalation part of the ongoing phase 1/2 LIBRA4 trial, patients with relapsed/refractory peripheral T cell lymphoma received T cell antigen receptor beta-chain constant domain 1 (TRBC1)-ta...
www.nature.com
November 18, 2024 at 2:44 AM